Fierce Pharma
OCTOBER 24, 2024
Results from two phase 3 trials show that GSK’s RSV vaccine Arexvy excelled in a broad age range of immunocompromised and other at-risk patients.
MedCity News
OCTOBER 24, 2024
Despite the challenges of interoperability, regulatory compliance, technology adoption, and data privacy, the benefits of digital health are undeniable. Collaboration between policymakers, clinicians, IT developers, and patients, can help overcome these obstacles. The post The Convergence of Digital Health and Life Sciences appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
OCTOBER 24, 2024
It’s déjà vu for Marnius Pharmaceuticals. | The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a cost-cutting scramble as it moves to explore "strategic alternatives.
MedCity News
OCTOBER 24, 2024
This week at HLTH, FDA Commissioner Robert Califf discussed the current state of healthcare AI. He talked about some of the qualms he has, such as his worry that AI is worsening health inequities and his concern that providers aren’t capable of validating AI tools’ effectiveness. The post 4 Things That Worry FDA Commissioner Robert Califf appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
OCTOBER 24, 2024
Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an accelerated approval filing for a kidney disease candidate. | Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an accelerated approval filing for a kidney disease candidate.
MedCity News
OCTOBER 24, 2024
Two chief information security officers offer some advice at a cybersecurity panel at HLTH. The post How To Spot Deepfakes and Other Cybersecurity Panel Takeaways from HLTH appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 24, 2024
As the field of oncology evolves, we need to shift away from traditional binary “yes-no” biomarkers to a more nuanced, spatial understanding of tumor biology. This approach will allow for more personalized treatment plans that are tailored to the unique characteristics of each patient’s tumor. The post Targeting the Blast Radius: Why Spatial AI Diagnostics Are Crucial for Maximizing the Impact of Antibody-Drug Conjugates appeared first on MedCity News.
PharmaTimes
OCTOBER 24, 2024
danicopan shown to improve haemoglobin levels and reduce anaemia
MedCity News
OCTOBER 24, 2024
Sach Jain, the CEO of Carrum Health, which helps self-insured employers manage their surgical care costs, had a sobering perspective at HLTH, a conference that celebrates innovation in healthcare. The post Video: Was Carrum’s CEO the Voice of Reason at HLTH? appeared first on MedCity News.
pharmaphorum
OCTOBER 24, 2024
WhatsApp message earns Moderna a reprimand under the ABPI Code, with Novo Nordisk, Otsuka, AstraZeneca and Daiichi Sankyo also breaching the rules
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
OCTOBER 24, 2024
Radiant Biotherapeutics’ Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup’s lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development. The post Gates Foundation Joins Radiant Bio’s $35M Round for Antibody Drugs With ‘Better Grip’ appeared first on MedCity News.
pharmaphorum
OCTOBER 24, 2024
Legal win leads Amgen to at-risk launch of Eylea biosimilar Phil.
Pharmaceutical Technology
OCTOBER 24, 2024
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of Wegovy and Ozempic.
pharmaphorum
OCTOBER 24, 2024
Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2.6 billion takeover of Longboard Pharma.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
PharmaTech
OCTOBER 24, 2024
Laks Pernenkil, Brian Feth, and Alex Philippidis go behind the headlines to discuss the impact of recent news, including FDA’s drug shortage list update, Nobel prize winners in microRNA and AI, and a big-potential research win for RNA editing.
Pharmaceutical Technology
OCTOBER 24, 2024
Nitrosamines are organic compounds that have gained attention in the pharma industry as impurities in manufacturing.
pharmaphorum
OCTOBER 24, 2024
Bayer partners medtech firm Impli on an implantable hormone biosensor with applications in fertility treatment and beyond.
PharmaVoice
OCTOBER 24, 2024
Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.
Pharmacy Times
OCTOBER 24, 2024
The FDA announces a Class II recall for the lot #220128, which were reported to contain the presence of nitrosamine.
PharmaTech
OCTOBER 24, 2024
In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at CRB Group, discusses how facilities used for solid dosage manufacturing may be retrofitted into sustainable cell and gene therapy production facilities.
Pharmaceutical Commerce
OCTOBER 24, 2024
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jeffrey Bernstein, director of cybersecurity and data privacy for Kaufman Rossin’s risk advisory services, forecasts how cyber threats could potentially evolve over the next decade.
Pharmaceutical Technology
OCTOBER 24, 2024
In pharma, smaller-scale AI and supervised machine learning models could provide more effective solutions than large language models (LLM).
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmacy Times
OCTOBER 24, 2024
The CDC Advisory Committee on Immunization Practice voted to expand the recommendation, which includes Prevnar 20 and Capvaxive.
PharmaTech
OCTOBER 24, 2024
Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.
Eversana Intouch
OCTOBER 24, 2024
In a recent article for PM360, Susan Perlbachs, Chief Creative Officer at EVERSANA INTOUCH, delves into the growing trend of celebrity influencers in pharmaceutical advertising, exploring both the opportunities and challenges they present. She highlights how celebrities can provide brands with instant recognition and broad reach, sharing examples like Travis Kelce’s involvement in Pfizer’s “Got Booster?
PharmaTech
OCTOBER 24, 2024
Merck is acquiring the Yale-spinout, which develops direct DNA modification-enabled cancer treatments.
Pharmacy Times
OCTOBER 24, 2024
Benjamin Brown of Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) discusses his own experience as a patient with cancer and how consensus around pharmacogenomic practices can improve the lives of patients.
Pharma Marketing Network
OCTOBER 24, 2024
The pharmaceutical industry is changing at lightning speed. New drugs, evolving technologies, and emerging marketing channels are creating fresh opportunities for pharma marketing executives. How do you keep up? As more patients turn to digital platforms for information and brands compete in an increasingly crowded market, pharma marketers need to be agile, creative, and tech-savvy to succeed.
Pharmacy Times
OCTOBER 24, 2024
Treatment with valacyclovir for a year decreased the risk of new or worsening eye disease by 26%.
PharmExec
OCTOBER 24, 2024
Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
294 
Let's personalize your content